Human Hp1-1 and Hp2-2 phenotype-specific haptoglobin therapeutics are both effective in vitro and in guinea pigs to attenuate hemoglobin toxicity

Antioxidants and Redox Signaling

Volumn 19, Issue 14, 2013, Pages 1619-1633

  Lipiski, Miriam ^a   Deuel, Jeremy W ^a   Baek, Jin Hyen ^b   Engelsberger, Wolfgang R ^a   Buehler, Paul W ^b   Schaer, Dominik J ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAPTOGLOBIN; HAPTOGLOBIN 1 1; HAPTOGLOBIN 2 2; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; GUINEA PIG; HEMOLYSIS; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; GUINEA PIGS; HAPTOGLOBINS; HEMOGLOBINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROGEN PEROXIDE; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE;

EID: 84878741762     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.5089     Document Type: Article

References (43)

1. Andersen CB, Torvund-Jensen M, Nielsen MJ, De Oliveira CL, Hersleth HP, Andersen NH, Pedersen JS, Andersen GR, and Moestrup SK. Structure of the haptoglobin-haemoglobin complex. Nature 489: 456-459, 2012
2. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, and Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res 96: 435-441, 2005
3. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, and Levy AP. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 92: 1193-1200, 2003
4. Baek JH, D'Agnillo F, Vallelian F, Pereira CP, Williams MC, Jia Y, Schaer DJ, and Buehler PW. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J Clin Invest 122: 1444-1458, 2012
5. Balla G, Jacob HS, Eaton JW, Belcher JD, and Vercellotti GM. Hemin: A possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler Thromb 11: 1700-1711, 1991
6. Balla J, Jacob HS, Balla G, Nath K, Eaton JW, and Vercellotti GM. Endothelial-cell heme uptake from heme proteins: Induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci U S A 90: 9285-9289, 1993
7. Balla J, Vercellotti GM, Jeney V, Yachie A, Varga Z, Jacob HS, Eaton JW, and Balla G. Heme, heme oxygenase, and ferritin: how the vascular endothelium survives (and dies) in an iron-rich environment. Antioxid Redox Signal 9: 2119-2137, 2007
8. Banerjee S, Jia Y, Siburt CJ, Abraham B, Wood F, Bonaventura C, Henkens R, Crumbliss AL, and Alayash AI. Haptoglobin alters oxygenation and oxidation of hemoglobin and decreases propagation of peroxide-induced oxidative reactions. Free Radic Biol Med 53: 1317-1326, 2012
9. Boretti FS, Buehler PW, D'Agnillo F, Kluge K, Glaus T, Butt OI, Jia Y, Goede J, Pereira CP, Maggiorini M, Schoedon G, Alayash AI, and Schaer DJ. Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs. J Clin Invest 119: 2271-2280, 2009
10. Buehler PW, Abraham B, Vallelian F, Linnemayr C, Pereira CP, Cipollo JF, Jia Y, Mikolajczyk M, Boretti FS, Schoedon G, Alayash AI, and Schaer DJ. Haptoglobin preserves the CD163 hemoglobin scavenger pathway by shielding hemoglobin from peroxidative modification. Blood 113: 2578-2586, 2009
11. Buehler PW, D'Agnillo F, and Schaer DJ. Hemoglobin-based oxygen carriers: From mechanisms of toxicity and clearance to rational drug design. Trends Mol Med 16: 447-457, 2010
12. Buehler PW, Vallelian F, Mikolajczyk MG, Schoedon G, Schweizer T, Alayash AI, and Schaer DJ. Structural stabilization in tetrameric or polymeric hemoglobin determines its interaction with endogenous antioxidant scavenger pathways. Antioxid Redox Signal 10: 1449-1462, 2008
13. Cahill LE, Levy AP, Chiuve SE, Jensen MK, Wang H, Shara NM, Blum S, Howard BV, Pai JK, Mukamal KJ, Rexrode KM, and Rimm EB. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol 61: 728-737, 2013
14. Cooper CE, Schaer DJ, Buehler PW, Wilson MT, Reeder BJ, Silkstone G, Svistunenko DA, Bulow L, and Alayash AI. Haptoglobin binding stabilizes hemoglobin ferryl iron and the globin radical on tyrosine beta145. Antioxid Redox Signal 18: 2264-2273, 2013
15. Dalton J, and Podmore A. Enriched haptoglobin polymers for the treatment of disease. US Patent Application 20110021418, 2011
16. Delanghe J, Allcock K, Langlois M, Claeys L, and De Buyzere M. Fast determination of haptoglobin phenotype and calculation of hemoglobin binding capacity using high pressure gel permeation chromatography. Clin Chim Acta 291: 43-51, 2000
17. Etzerodt A, Kjolby M, Nielsen MJ, Maniecki M, Svendsen P, and Moestrup SK. Plasma clearance of hemoglobin and haptoglobin in mice and effect of CD163 gene targeting disruption. Antioxid Redox Signal 18: 2254-2263, 2013
18. Gattoni M, Boffi A, Sarti P, and Chiancone E. Stability of the heme-globin linkage in alphabeta dimers and isolated chains of human hemoglobin. A study of the heme transfer reaction from the immobilized proteins to albumin. J Biol Chem 271: 10130-10136, 1996
19. Gladwin MT, Kanias T, and Kim-Shapiro DB. Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease. J Clin Invest 122: 1205-1208, 2012
20. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, and Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature 409: 198-201, 2001
21. Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Kalet-Litman S, Anbinder Y, Lache O, Nakhoul FM, Asaf R, Farbstein D, Pollak M, Soloveichik YZ, Strauss M, Alshiek J, Livshits A, Schwartz A, Awad H, Jad K, and Goldenstein H. Haptoglobin: Basic and clinical aspects. Antioxid Redox Signal 12: 293-304, 2010
22. Levy AP, Levy JE, Kalet-Litman S, Miller-Lotan R, Levy NS, Asaf R, Guetta J, Yang C, Purushothaman KR, Fuster V, and Moreno PR. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 27: 134-140, 2007
23. Levy AP, Purushothaman KR, Levy NS, Purushothaman M, Strauss M, Asleh R, Marsh S, Cohen O, Moestrup SK, Moller HJ, Zias EA, Benhayon D, Fuster V, and Moreno PR. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: Implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 101: 106-110, 2007
24. Miller YI, Altamentova SM, and Shaklai N. Oxidation of low-density lipoprotein by hemoglobin stems from a hemeinitiated globin radical: Antioxidant role of haptoglobin. Biochemistry 36: 12189-12198, 1997
25. Miller YI, Smith A, Morgan WT, and Shaklai N. Role of hemopexin in protection of low-density lipoprotein against hemoglobin-induced oxidation. Biochemistry 35: 13112-13117, 1996
26. Moreno PR, Purushothaman KR, Purushothaman M, Muntner P, Levy NS, Fuster V, Fallon JT, Lento PA, Winterstern A, and Levy AP. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol 52: 1049-1051, 2008
27. Nagy E, Eaton JW, Jeney V, Soares MP, Varga Z, Galajda Z, Szentmiklosi J, Mehes G, Csonka T, Smith A, Vercellotti GM, Balla G, and Balla J. Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler Thromb Vasc Biol 30: 1347-1353, 2010
28. Nakai K, Sakuma I, Ohta T, Ando J, Kitabatake A, Nakazato Y, and Takahashi TA. Permeability characteristics of hemoglobin derivatives across cultured endothelial cell monolayers. J Lab Clin Med 132: 313-319, 1998
29. Noyes WD, and Garby L. Rate of haptoglobin in synthesis in normal man. Determinations by the return to normal levels following hemoglobin infusion. Scand J Clin Lab Invest 20: 33-38, 1967
30. Osada J. Elimination from rat circulation of goat and sheep haptoglobin and their complexes with rat haemoglobin. Acta Biochim Pol 35: 169-175, 1988
31. Osada J, and Nowacki W. Elimination of goat haemoglobin and its complexes with goat haptoglobin from goat and rat circulation. Acta Biochim Pol 36: 365-369, 1989
32. Pimenova T, Pereira CP, Gehrig P, Buehler PW, Schaer DJ, and Zenobi R. Quantitative mass spectrometry defines an oxidative hotspot in hemoglobin that is specifically protected by haptoglobin. J Proteome Res 9: 4061-4070, 2010
33. Purushothaman KR, Purushothaman M, Levy AP, Lento PA, Evrard S, Kovacic JC, Briley-Saebo KC, Tsimikas S, Witztum JL, Krishnan P, Kini A, Fayad ZA, Fuster V, Sharma SK, and Moreno PR. Increased expression of oxidation-specific epitopes and apoptosis are associated with haptoglobin genotype: Possible implications for plaque progression in human atherosclerosis. J Am Coll Cardiol 60: 112-119, 2012
34. Ratanasopa K, Chakane S, Ilyas M, Nantasenamat C, and Bulow L. Trapping of human hemoglobin by haptoglobin: Molecular mechanisms and clinical applications. Antioxid Redox Signal 18: 2364-2374, 2013
35. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, 3rd, Schechter AN, and Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8: 1383-1389, 2002
36. Schaer CA, Schoedon G, Imhof A, Kurrer MO, and Schaer DJ. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res 99: 943-950, 2006
37. Schaer CA, Vallelian F, Imhof A, Schoedon G, and Schaer DJ. CD163-expressing monocytes constitute an endotoxinsensitive Hb clearance compartment within the vascular system. J Leukoc Biol 82: 106-110, 2007
38. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, and Vercellotti GM. Hemolysis and free hemoglobin revisited: Exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 121: 1276-1284, 2013
39. Schaer DJ, Schaer CA, Buehler PW, Boykins RA, Schoedon G, Alayash AI, and Schaffner A. CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood 107: 373-380, 2006
40. Shen H, Song Y, Colangelo CM, Wu T, Bruce C, Scabia G, Galan A, Maffei M, and Goldstein DR. Haptoglobin activates innate immunity to enhance acute transplant rejection in mice. J Clin Invest 122: 383-387, 2012
41. Vallelian F, Pimenova T, Pereira CP, Abraham B, Mikolajczyk MG, Schoedon G, Zenobi R, Alayash AI, Buehler PW, and Schaer DJ. The reaction of hydrogen peroxide with hemoglobin induces extensive alpha-globin crosslinking and impairs the interaction of hemoglobin with endogenous scavenger pathways. Free Radic Biol Med 45: 1150-1158, 2008
42. Wicher KB, and Fries E. Evolutionary aspects of hemoglobin scavengers. Antioxid Redox Signal 12: 249-259, 2010
43. Wuyts B, Delanghe JR, Kasvosve I, Langlois MR, De Buyzere ML, and Janssens J. A new method for fast haptoglobin phenotyping and hemoglobin binding capacity calculation based on capillary zone electrophoresis. Clin Chem Lab Med 38: 715-720, 2000